Left-handedness, learning disability, autoimmune disease, and seizure history influence age at onset and phenotypical targeting of Alzheimer's disease
Miller, Z. A.; Ossenkoppele, R.; Graff-Radford, N. R.; Allen, I. E.; Shwe, W.; Rosenberg, L.; Olguin, D. J.; Erkkinen, M. G.; Butler, P. M.; Spina, S.; Yokoyama, J. S.; Desikan, R. S.; Scheltens, P.; van der Flier, W.; Pijnenburg, Y.; Wolters, E.; Rademakers, R.; Geschwind, D. H.; Kramer, J. H.; Rosen, H. J.; Rankin, K. P.; Grinberg, L. T.; Seeley, W. W.; Sturm, V.; Perry, D. C.; Miller, B. L.; Rabinovici, G. D.; Gorno-Tempini, M. L.
Show abstract
BackgroundRisk factors associated with sporadic non-amnestic and early-onset Alzheimers disease remain underexamined. We investigated a large, clinically heterogeneous Alzheimers disease cohort for frequencies of established Alzheimers disease risk factors (hypertension, hyperlipidemia, diabetes mellitus, APOE-{varepsilon}4 frequency, and years of education), alongside a suite of novel factors with historical theoretical association (non-right-handedness, learning disability, seizures, and autoimmune disease). MethodsIn this case-control study, we screened the demographic and health histories of 750 consecutive early-onset and 750 late-onset Alzheimers disease patients from the University of California San Francisco Memory and Aging Center for the prevalence of conventional risk and novel Alzheimers disease factors and compared these results with 8,859 Alzheimers disease individuals from the National Alzheimers Coordinating Center, Amsterdam University Medical Center, Amsterdam, and Mayo Clinic, Jacksonville. ResultsEarly-onset Alzheimers disease was associated with significantly lower frequencies of established risk factors (hypertension, hyperlipidemia, diabetes mellitus, all p<0.001, APOE-{varepsilon}4, p=0.03) and significantly higher frequencies of novel factors (non-right-handedness, learning disability, active seizure, all p<0.001, remote seizure, p=0.002, and autoimmune disease, p=0.007). Logistic regressions predicting EOAD vs. LOAD controlling for sex, education, APOE-{varepsilon}4 status, typical, and novel risk factors, produced findings consistent with the above. Principal component analysis loaded novel factors into two components, non-right-handedness and learning disability versus seizure and autoimmune disease, and the combination of factors from both components resulted in an exponential decrease in age at onset from any single factor alone. APOE-{varepsilon}4 provided no additional contribution to age at onset decreases within the non-amnestic Alzheimers disease cohort but shifted the age of onset 3 years earlier within amnestic presentations (p=0.013). ConclusionsWe identified non-right-handedness, learning disability, seizures, and autoimmune disease as novel factors that affect both the age at onset and phenotypical targeting of Alzheimers disease. Together these results support a new theoretical framework of neurodegenerative disease susceptibility and that through the collection of detailed developmental and health history, neurodegenerative disease risk in some may be highly predictable, offering new opportunities towards early detection, monitoring, therapeutic intervention, and ultimately disease prevention.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research 95%
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 94%
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 93%
Similar papers in this journal
- Exploring the genetic heterogeneity of Alzheimer’s disease: Evidence for genetic subtypes 95%
- Frequency of Variants in Mendelian Alzheimer’s Disease Genes within the Alzheimer’s Disease Sequencing Project (ADSP) 95%
- Staging Alzheimer’s disease in the brain and retina of B6.APP/PS1 mice by transcriptional profiling 93%